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Variegate porphyria (VP) is an autosomal dominantly inherited hepatic porphyria. The genetic defect in the PPOX
gene leads to a partial defect of protoporphyrinogen oxidase, the penultimate enzyme of heme biosynthesis.
Affected individuals can develop cutaneous symptoms in sun-exposed areas of the skin and/or neuropsychiatric
acute attacks. The identification of the genetic defect in VP families is of crucial importance to detect the carrier
status which allows counseling to prevent potentially life threatening neurovisceral attacks, usually triggered by
factors such as certain drugs, alcohol or fasting.
In a total of 31 Swedish VP families sequence analysis had identified a genetic defect in 26. In the remaining five
families an extended genetic investigation was necessary. After the development of a synthetic probe set, MLPA
analysis to screen for single exon deletions/duplications was performed.
We describe here, for the first time, two partial deletions within the PPOX gene detected by MLPA analysis. One
deletion affects exon 5 and 6 (c.339-197_616+320del1099) and has been identified in four families, most probably
after a founder effect. The other extends from exon 5 to exon 9 (c.339-350_987+229del2609) and was found in one
family. We show that both deletions are mediated by Alu repeats.
Our findings emphasize the usefulness of MLPA analysis as a complement to PPOX gene sequencing analysis for
comprehensive genetic diagnostics in patients with VP.
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Variegate porphyria (VP, OMIM 176200) is an autosomal
dominant disease caused by mutations in the protopor-
phyrinogen oxidase (PPOX) gene, causing a partial defect
of the seventh catalytic step of the haem biosynthetic path-
way. The enzyme protoporphyrinogen oxidase (PPOX)
[EC 1.3.3.4] may become overloaded under conditions with
high demand of hepatic haem biosynthesis leading to the
accumulation of phototoxic and/or neurotoxic metabolites.
Thus VP is a mixed form of cutaneous and acute porphy-
ria. Overt disease is associated with skin photosensitivity* Correspondence: ylva.floderus@karolinska.se
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reproduction in any medium, provided the orand/or neurogenic symptoms as acute attacks of severe ab-
dominal pain, autonomic disturbance, motor neuropathy
and more rarely even psychiatric symptoms [1].
The clinical penetrance of VP is about 40% [2,3] and
symptoms almost never manifest before puberty. Skin
symptoms are manifest as skin fragility and blistering in
sun exposed areas of the body, and are caused by the accu-
mulation of protoporphyrinogen (the substrate of PPOX)
in the skin. The skin symptoms are the same as those pre-
sented in porphyria cutanea tarda (PCT) and hereditary
coproporphyria (HCP). The neurovisceral symptoms are
undistinguishable from those for acute intermittent porphy-
ria (AIP) or HCP. Surplus protoporphyrinogen may cause
an allosteric inhibition of porphobilinogen deaminase
(PBGD, the third enzyme in the haem biosynthetic path-
way) leading to accumulation of the neurotoxic metabolitesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(PBG) [4].
During overt disease the diagnosis of VP is based on
clinical symptoms and biochemical laboratory investiga-
tions. The porphyrin biochemical pattern characteristic
for VP is the presence of a plasma fluorescence marker
with a maximum peak at 624 – 627 nm, increased faecal
protoporphyrin and inversed coproporphyrin isomer ratio
(i.e. copro III isomer > copro I isomer; normal I > III). The
urinary porphyrin metabolite pattern may be normal or
abnormal with increased excretion of ALA, PBG and
coproporphyrin depending on the degree of the metabolic
overload of the haem biosynthetic pathway. Erythrocyte
porphyrin concentration is usually normal. The activity of
the PPOX enzyme, located in the mitochondrial mem-
brane, is measured in lymphocytes or fibroblasts [4]. Fur-
ther DNA investigations are usually required in order to
easily detect asymptomatic/latent relatives [5]. The detec-
tion of carriers is of extreme importance and VP patients
or latent carriers, as in all acute porphyrias, shall be encour-
aged to avoid porphyrogenic agents as e.g. certain drugs,
alcohol and low carbohydrate diets etc. [6,7].
The PPOX gene is located on chromosome 1q22-23, has
a size of 5.5 kb and contains 13 exons, one non-coding and
12 coding that encode the 477 amino acid PPOX enzyme.
The prevalence of VP in Sweden has been estimated
to be 1:100 000 and the mutation pattern in fourteenFigure 1 Pedigrees of VP families carrying partial PPOX deletion. Pedi
results and markers for biochemical symptoms. In families A-D affected me
exon 5–9 deletion. Members in family A-D for whom neither biochemical
simplification.families has been reported [5]. Before the present study a
total of 20 different mutations have been found among the
Swedish VP patients (unpublished data). Homozygous or
compound heterozygous mutations, with seriously com-
prised phenotype since early childhood, have been
described [8-10] but no such cases have been identified in
Sweden.
In five families with well established clinical and bio-
chemical VP diagnosis, the underlying gene defect was not
detected by routine DNA sequencing analysis. The aim of
this study was to develop a MLPA probe set to screen for
possible deletions/duplications affecting the PPOX gene in
these families.Patients and methods
Patients
Patients, biochemically confirmed to be affected by VP, in
which PPOX routine analysis by PCR and sequencing had
failed to identify a disease causing mutation have been
selected for this study. The patients included in this study
belong to five apparently unrelated Swedish families
(Figure 1). The genetic analysis, that includes 845 nucleo-
tides of the promoter region and the non-coding exon 1 of
the PPOX gene, as well as the biochemical investigations
used to identify patients and latent carriers have been previ-
ously described [5].grees of the five families carrying partial PPOX deletion with DNA
mbers carry an exon 5–6 deletion. In family E the patient carries an
nor genetic investigation were performed are omitted for
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DNA
Genomic DNA was extracted from peripheral blood sam-
ples by the QIAamp DNA Mini kit (QIAGEN, Hilden,
Germany), according to the manufacturer’s protocol.
MLPA probe set development and analysis
The target sequence of each synthetic half probe was
designed according to the recommendations by Stern et al.
[11]. One probe pair for each exon of the PPOX gene was
designed, including the first non-coding exon. In the probe
set three internal control probe pairs and a pilot probe pair
were included [12] as well as a probe targeting the SRY
gene on the Y chromosome to control the correct order of
sample loading (see Table 1). MLPA reactions were per-
formed as previously described [12], starting from 100 ng
of genomic DNA and using the reagents and the recom-
mendations of the EK1 MLPA reagent kit (MRC-Holland,
Amsterdam, The Netherlands). The PCR products were
separated by capillary electrophoresis on an ABI 3130XL
Genetic Analyzer (Applied Biosystems, Warrington, UK).
Trace data were analyzed using the Gene Mapper v4.0
software (Applied Biosystems), and the integrated peak
areas and heights were exported to an Excel spreadsheet
(Microsoft, Silicon Valley, CA). For each sample, the peak
heights were first normalized to the average peak height of
the control probes followed by normalization to the average
peak height of the control samples included in the run. The
sample run was considered acceptable if the ratio for the
internal control probe pairs was between 0.8 and 1.2.
Threshold values for deletion and duplication were set at
0.75 and 1.25, respectively.
Deletion breakpoint characterization
Amplifications of the deletion junctions were performed
using a forward primer within intron 3 (50-TTGG
TGGGTCAGATCTTC-30) in combination with a reverse
primer within intron 7 (50-CACTGACAGGTTCATTAC
AC-30) for the exon 5–6 deletion or a reverse primer
within intron 10 (50-CCTAAGGAGGGAATATAGC
ACTG-30) for the exon 5–9 deletion. PCR was carried
out in a 50 μl reaction mixture containing 100 ng
genomic DNA, 0.4 μM of each primer, 200 μM of each
dNTPs, 1X PCR buffer F514L (Finnzyme, Espoo,
Finland) and 0.5 U DyNAzyme EXT DNA polymerase
(Finnzyme). After an initial denaturing step at 94°C for
2 min, 39 cycles, consisting of denaturation at 94°C for
30 sec, annealing at 57°C for 30 sec and elongation at
70°C for 1 min, were carried out, followed by a final
elongation step at 70°C for 10 min. A total of 45 μl of
PCR products were purified with the AgentcourtW
Ampure kit (Beckman Coulter, Brea, CA).Sequencing reactions of PCR products were performed
using the ABI Big Dye Terminator v3.1 kit (Applied
Biosystems) followed by ethanol precipitation in a 96-well
plate according to manufacturer’s protocol, using the same
primer as used for the PCR reaction. Sequence reactions
were separated by capillary electrophoresis in an ABI
3130XL Genetic Analyzer (Applied Biosystems) and elec-
tropherograms were visualized by Sequence Scanner v1.0
(Applied Biosystems).
Haplotyping
By routine sequencing analysis of the PPOX gene in some
members of the four families we determined an intragenic
SNP haplotype of the allele carrying the exon 5–6
deletion. The SNPs considered are the validated SNPs
from dbSNP [13] within the coding sequence; rs2301286
and rs72714915 within the 50 UTR and rs2301287 within
intron 2 have also been included as data were available
from routine analysis and they are quite variable within
the Swedish population (Table 2).
Results
MLPA analysis
The performance of the PPOX probe set (Table 1) was
tested using DNA samples from 11 normal controls. All
probes presented a SD <10%, thus proving to have a reli-
able and sufficiently consistent performance.
At least one affected member for each family was ana-
lyzed by MLPA. Patient samples belonging to families A,
B, C and D showed ratio values consistent with a hetero-
zygous deletion for the probes within exons 5 and 6
(Figure 2). The sample belonging to the patient in family E
showed a deletion extending from exon 5 to exon 9
(Figure 2).
To identify all the carriers of the deletions, all available
family members were analyzed by MLPA or PCR; the fam-
ily trees in Figure 1 summarize the results obtained.
Deletion characterization
To confirm and fine map the deletions, the deletion
junctions were amplified and sequenced. Using a
forward primer within intron 3 and a reverse primer
within intron 7, the PCR product in a normal control
gave a band of 1904 bp, while in the samples with the
exons 5–6 deletion a band of approximately 1 kb was
obtained. By sequencing we could also establish that in
all four families the affected members share the same
deletion of 1099 bp. According to the Human Gene
Variation Society [14] the deletion can be described as
c.339-197_616+320del1099bp, using the reference se-
quence NM_000309.3.
In family E the PCR product in the patient had a size
of approximately 0.7 kb instead of the wild type size of
3305 bp. By sequencing we determined that the deletion
Table 1 PPOX probe mix
Probe name Sizea 50half hyb sequenceb 30half hyb sequencec SD N1 N2 Fam A Fam E
GABRA4d 84 CAGCCTGTTGTCATAACCATCG AGCAAACTGTCCAGGATGCG 0.20 nd nd nd nd
RELNe 87 CAGCATTACGGAATGAAGGTCA CCACAAGAAGTGGCTTCACAACC 0.04 1.02 0.99 0.98 0.96
PPOXex1 90 GGGAGTAGCGGATTTGAAGCACTT GTTGGCCTACAGAGGTGTGGCAAG 0.03 0.94 1.00 1.07 1.01
PPOXex7v3 93 CTGAGCGCTGGAGCCAGTGGTCACTT CGTGGAGGTCTAGAGATGTTGCCTC 0.04 1.00 0.99 1.03 0.55
PPOXex5v5 96 GCAAAGAGCCTGATGAGACTGTGC ACAGTTTTGCCCAGCGCCGCCTTGGACCTG 0.03 1.04 1.00 0.57 0.60
PPOXex6 99 GTGTTTGCAGGCAACAGCCGTGAGCTCA GCATCAGGTCCTGCTTTCCCAGTCTCTTC 0.03 1.02 1.02 0.59 0.58
PPOXex3 102 GCTCCGTTCGAGGCCCTAATGGTGCTATCT TTGAGCTTGGACCTCGGGGAATTAGGCCAG 0.02 1.00 0.93 1.04 1.11
CLDN16e 105 GACACAAGGGTGTAAAATGCACG TTTCAGGGTGTGTTTGCATATGATTTAATCAATCAGTATG 0.04 1.00 1.02 1.01 1.00
PPOXex9 108 GTGCCATCACTGCAGTGTCTGTAGCTGTGGTGA ATCTGCAGTACCAAGGAGCCCATCTGCCTGTCC 0.03 1.05 0.99 1.02 0.58
PPOXex11 111 CTGTTTCAACAGCGGGCCCAGGAAGCAGCTGCTA CACAATTAGGACTGAAGGAGATGCCGAGCCACTGC 0.03 1.04 1.04 0.99 1.22
PPOXex4 114 CATGCCCTACCCACTGGCCTCAGGTAACACCAGCA CCTCCGCTCCTTTTACTGTGCCCTCATCCTCATATGC 0.02 1.05 1.03 1.06 1.16
PPOXex8 117 CTCATTTTCTGGGTCTCTCAAATGTTTTCATGCTCTC AGGTATCTCTAAGGGACAGCAGTCTGGAGGCTGACCAC 0.04 1.06 1.03 0.98 0.56
PPOXex12 120 CTGGCAAAAACTAGGTAAGTTGGGAAAACAGCTGGGCT GAGGAGGGCCAAGGACATCAGACCCCCAGCTAAAACATTC 0.03 1.06 1.09 0.99 1.16
PPOXex10 123 CTGACGCATGAATGTCCTTCTCTCCAGGGATTTGGACATT TGGTGCCATCTTCAGAAGATCCAGGAGTCCTGGGAATCGTG 0.03 1.06 1.09 0.93 1.16
PPOXex13 126 GCTGTTAATGACTGTATAGAGAGTGGGCGCCAGGCAGCAGTCA GTGTCCTGGGCACAGAACCTAACAGCTGATCCCCAACTCTC 0.03 1.08 1.03 1.04 1.13
RB1ex23e 129 GTCACCAATACCTCACATTCCTCGAAGCCCTTACAAGTTTCCT AGTTCACCCTTACGGATTCCTGGAGGGAACATCTATATTTCACC 0.02 1.00 1.02 0.98 1.11
PPOXex2v4 132 CCTAAGGTGAGTGCTCCACTTGTGCCAGAGGGAGCTTCATTTAATGC TCTTCCCATTTCCATCAAAAGCTAGATGGATCCTGGCCCTCTG 0.02 1.01 1.00 1.09 1.08
SRY 135 CAGTGCAAAGGAAGGAAGAGCTTCTCCGGAGAGCGGGAATATTCT CTTGCACAGCTGGACTGTAATCATCGCTGTTGAATACGCTTAACATAG nd nd nd nd nd
aSize of the ligaton product in bp.
bThe 50 half-probes are preceded by the universal tag sequence GGGTTCCCTAAGGGTTGGA.























Table 2 Haplotypes in the allele with the exon 5–6 deletion
SNP SNP alleles Location Average
Heterozygosity




rs2301286 A/C Exon 1 UTR 0.397 A = 0.3832 C C C C C A/C
rs115158839 G/T Exon 1 UTR 0.033 T = 0.006 G G G G G G
rs72714915 C/G Exon 1 UTR 0.095 G = 0.0367 C C C C C C/G
rs2301287 C/G Intron 2 0.444 G = 0.3759 C C C C C C/G
rs12030747 G/A Exon 7 (Glu234Lys) 0.013 NA G G G G G G
rs36013429 G/A Exon 9 (His304Arg) 0.008 A = 0.0476 G G G G G G/A
MAF minor allele frequency.
NA not available.
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350_987+229del2609bp.
Haplotype analysis
Patients belonging to the four different families with the
exon 5–6 deletion share, on the allele with the deletion,













Figure 2 PPOX probe set MLPA results. (A). MLPA trace results for the P
normal controls (N1 and N2) used as reference. Peaks corresponding to co
the numbers indicate the PPOX exon to which the peak corresponds; P the
probes. (B). Graph showing the analysis results from Excel. Probes on the P
Internal reference probes are included and show a ratio value near 1. The r
corresponding probes.Discussion
VP is caused by mutations in the PPOX gene. All the 150
mutations reported so far are point mutations or small
insertions or deletions [15] with the largest deletion being
23 bp long [16], all of them detectable by a PCR and se-
quencing approach. In our patient population we had failed










POX probe set in patients belonging to VP families A and E, and two
ntrol probes are labeled (*). On the X-axis at the bottom of the figure
pilot probe; R the reference probes. Red arrows indicate the deleted
POX gene are ordered according to their location along the gene.













AluSg(int9)(+)    5’-AGGCAGGAGAATCGCTTGAACCCAGGAGGTGGAGGTTGCAGTGAGCTGAGATCTC-3’
Junction (+) 5’-GCAATGGCGCGATCTTGGCTCACTGCAGGTGGAGGTTGCAGTGAGCTGAGATCTC-3’
AluSg(int4)(+) 5’-GCAATGGCGCGATCTTGGCTCACTGCAACTTCCGCCTTTCGGGTTCAAGCGATTC-3’
| ||||||| |||||  |||||||||||| ||| |||   |||||||||||||||
AluSg(int9)(-) 5’-GTAATGGCGAGATCTCAGCTCACTGCAACCTCCACCTCCTGGGTTCAAGCGATTC-3’
AluSg(int9)(+)    3’-CATTACCGCTCTAGAGTCGAGTGACGTTGGAGGTGGAGGACCCAAGTTCGCTAAG-5’
Figure 3 PPOX MLPA probe set and deletion characterizations. (A). Representation from the UCSC genome browser (Mar2006. NCBI36, hg18)
of the protoporphyrinogen (PPOX) gene locus on 1q22-23. Probes included in the 'PPOX MLPA probe set' are represented as vertical red lines.
Deletions are represented by horizontal green lines. Repeats identified by Repeat Masker are represented by black boxes, arrows underneath
indicate the respective genomic orientation. The colour of the arrow is used to highlight the sequence of the corresponding Alu in the sequence
analysis showed below. (B). Sequence analysis of the exon 5–6 deletion junction. Partial alignment of the AluSg within intron 4, the deletion
junction sequence and the AluSx within intron 6. Single nucleotide differences between the two Alu repeats are denoted by an asterisk (*).
Nucleotides in the region of complete homology are bolded. (C). Sequence analysis of the exon 5–9 deletion junction. Partial alignment of the
deletion junction with the AluSg within intron 4 and within intron 9, respectively. The two nucleotides at the junction site are bolded. (D). Partial
alignment between the AluSg within intron 4 and the AluSg within intron 9, showing the homology between the two AluSg and their inverted
orientation. Vertical lines denote identical nucleotides; (+) and (−) indicate the positive and negative filament, respectively. The junction sequence
and the positive filament of intron 9 AluSg are shown together with arrows to facilitate the understanding of the rearrangement.
Barbaro et al. Orphanet Journal of Rare Diseases 2013, 8:13 Page 6 of 8
http://www.ojrd.com/content/8/1/13routine sequence analysis. We have therefore developed a
MLPA probe set to screen for deletion/duplication of each
exon of the PPOX gene that would escape detection by
PCR and sequencing.
We identified two deletions, one affecting exon 5 and 6
and the other extending from exon 5 to exon 9. These are
the first partial deletions of the PPOX gene described so far.
Both deletions are mediated by Alu sequences. For the
exon 5–6 deletion, in silico analysis identified a 308 bp
AluSg element within intron 4 and a 353 bp AluSz element
within the intron 6 that share 80% identity, according to
BLASTN alignment [17]. Sequencing of the deletion junc-
tion identified the breakpoint within a 12 bp interval of
complete homology (Figure 3). As the two Alu elements be-
long to two different subfamilies and do not share a longstretch of extremely high identity required for homologous
recombination, an Alu-mediated non-allelic homologous
recombination mechanism (NAHR) is unlikely to be re-
sponsible for the deletion. An Alu-specific microhomology-
mediated deletion is the most likely mechanism [18]. Since
we found the same deletion in four independent families we
further collected pedigree information and analyzed the
gene haplotype to evaluate if this deletion occurred inde-
pendently due to a recurrent deletion mechanism or if there
was a possible founder effect. Patients belonging to the four
different families share the same intragenic SNP haplotype
on the allele with the exon 5–6 deletion. Furthermore, the
oldest family members who are potential carriers of the
mutation were born in three neighbouring parishes in the
South East of Sweden. Even if we could not find a common
Barbaro et al. Orphanet Journal of Rare Diseases 2013, 8:13 Page 7 of 8
http://www.ojrd.com/content/8/1/13ancestor between them, it is very likely that they are related,
thus suggesting a founder effect for this mutation rather
than a recurrent deletion mechanism. This could represent
an example of clan genomics: a recently developed mutation
of clinical relevance spreading in a specific population [19].
For the exon 5–9 deletion, in silico analysis determined
that the 308 bp AluSg element within intron 4 share also
87% identity with a 278 bp AluSg located within intron 9
with an inverted orientation. Sequencing of the breakpoint
region doesn’t show a minimal region of homology. It is
thus impossible to discriminate if this deletion is mediated
by a recombination based mechanism such as NHEJ
(non-homologous end joining ) or by a single event of a
replication-based mechanism like FoSTeS (Fork Stalling
and template switching) or MMBIR (microhomology-
mediated break-induced replication) [18,20].
Alu-mediated genomic rearrangements have been shown
to be involved in 0.3% of human genetic disease [21] where
they can be responsible for both recurrent and non-
recurrent rearrangements [22]. Interestingly the AluSg
within intron 9 shares 80% identity and has inverted orien-
tation not only with respect to the AluSg within intron 4,
where it is involved in the exon 5–9 deletion, but also with
respect to the AluSz within intron 6. As inverted Alu
repeats are a threat to genome stability [23], PPOX can be
considered at risk for more genetic rearrangements.
Most of the adults positive for the exon 5–6 deletion
have presented with biochemical markers indicating VP,
mainly typical plasma fluorescence marker and increased
faecal porphyrins, with dominance of coproporphyrin III
isomer. Clinical symptoms such as skin blisters and/or
neuropsychiatric symptoms have been present in several
patients and some have previously been misdiagnosed as
PCT or AIP, Patient A IV:4 had at her fourth decade of life
suffered from severe neuropsychiatric symptoms, abdom-
inal pain, motor neuropathies and periods of hallucinosis.
She has later in life developed skin blisters. Patient B V:2
presented with abdominal pain and neurological symp-
toms at the age of 21 and had an AIP diagnosis at 24. Dur-
ing the fourth decade of life she presented skin symptoms
and was diagnosed as PCT. At present she is asymptom-
atic but has a chronic hypertension and decreased kidney
function. Patient D II:1 at the age of 30 had skin lesions
resembling PCT and during anaesthesia (caesarean) she
developed paralysis of facial muscles. Patient C I:1 was
diagnosed at the age of 48 with PCT and later developed
as well periods of abdominal pain, depression and mild
psychosis. VP diagnosis was lately biochemically confirmed
at the age of 77. At that time he had normal excretion of
urinary haem precursors but several-fold increased faecal
porphyrins and a distinct fluorescence marker in plasma
(627 nm). He died at the age of 88 years. His daughter was
identified by genetic analysis at the age of 55. She has been
clinically latent and has weak biochemical markers. Twoyounger carrier members in Family A (V:1 and VI:1) at the
age of 26 and 14 respectively, show neither biochemical
signs nor clinical symptoms yet. The patient E I:1 with the
exon 5–9 deletion was diagnosed at age 27 after a period of
abdominal pain. She has also had temporary skin symp-
toms. At present she has hypertension and end stage renal
disease.
Despite sharing the same mutation these patients present
extensive phenotype variation and early diagnosis is of main
importance to prevent outbreak of clinical symptoms.
Acute porphyria carriers above the age of 50 should be
included in yearly liver screening programme including
radiological investigation in order to detect primary liver
cancer, a known common complication in acute hepatic
porphyria [24-27].
Gene dosage analysis has earlier been shown to increase
the diagnostic sensitivity for the two other acute porphyrias
(AIP and HCP) [28] and large deletions have been reported
for the HMBS and CPOX genes, respectively [28-30]. We
describe here two partial deletions within the PPOX gene,
indicating that partial gene deletions should be considered
in the genetic diagnosis of all acute porphyrias. The MLPA
probe set we have developed represents a useful tool for
the identification of such mutations, and should be per-
formed to complement PPOX sequencing analysis.
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